Although initially developed as an ALK and c-MET inhibitor, it showed significant efficacy against ROS1-fusion NSCLC and was approved for this indication in 2016, five years after its approval for ALK+ NSCLC. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.